NCI is collaborating with the U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) on two new funding opportunities to support the small business community in developing regulatory science tools. The following topics are now being offered as part of the FY 2022-1 SBIR Contract Solicitation, with the aim to bridge the gap between research of medical devices and the delivery of devices to patient:
Quantitative Biomarkers as Medical Device Development Tools for Cancer: Potential examples include new/high resolution multimodal imaging as biomarkers for detection of various melanomas or difficult to biopsy tumors, or laboratory-based biomarker tests to be used to help regulatory evaluation of diagnostic and therapeutic medical products.
Evaluation Datasets as Medical Device Development Tools for Testing Cancer Technologies: Potential datatypes of interest cover a broad range of data produced by medical devices, especially datasets to evaluate artificial intelligence software, and include imaging (radiology and pathology), cancer genomics, proteomics, structured data extracted from unstructured EHR, and treatment outcome data.
To learn more about these opportunities and what they mean for your biotech commercialization journey, join experts from NCI SBIR and FDA's CDRH for a joint informational webinar on Tuesday, August 24th at 2-3 PM EDT as they discuss these funding opportunities, MDDT Program requirements, small business eligibility criteria, and more.